Featured Research

from universities, journals, and other organizations

Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests

Date:
November 11, 2012
Source:
American College of Rheumatology (ACR)
Summary:
A new study suggests that anti-tumor necrosis factor drugs (also called anti-TNF) offer no relief to patients with chronic pain caused from hand osteoarthritis.

A new study presented this week at the American College of Rheumatology Annual Meeting in Washington D.C., suggests that anti-tumor necrosis factor drugs (also called anti-TNF) offer no relief to patients with chronic pain caused from hand osteoarthritis.

Osteoarthritis, or OA as it is commonly called, is the most common joint disease affecting middle-age and older people. It is characterized by progressive damage to the joint cartilage -- the cushioning material at the end of long bones. It can causes changes in the structures around the joint including fluid accumulation, bony overgrowth, and weakness of muscles and tendons, all of which may limit movement and cause pain and swelling.

People with hand osteoarthritis often experience pain in multiple joints and previous studies have documented that the disease does not respond to several of the traditional therapies used in its treatment. However, anti-TNF medications may represent a real hope, because TNF is a molecule found to contribute to the destruction of cartilage and inflammation of joints. Researchers on behalf of the French National Section on OA (led by the Hopital Henri Mondor ) in France recently compared the effectiveness of TNF blockers (commonly called anti-TNFs) and nonsteroidal anti-inflammatory drugs (also called NSAIDs) in controlling pain in people with hand OA.

The digital osteoarthritis in refractory hand OA study (called DORA) included hand OA patients who did not respond to painkillers and NSAIDs. Patients also had to meet the American College of Rheumatology criteria for hand OA with significant pain, at least three painful inter phalangeal hand joints and a minimum of three involved joints identified by X-ray. The study was conducted at 16 different clinical sites. Eighty-five patients were randomly divided into two groups. One group received adalimumab (Humiraฎ), and the other group received placebo. Neither the patients nor the researchers were told who was in which group. Patients were monitored for 26 weeks. Those in the adalimumab group received two injections of the therapy at the beginning and second week of the trial.

Researchers established that a change of more than 50 percent in improvement in pain score after six weeks would be considered therapeutic success. Additional signs of success after six weeks included fewer painful and swollen joints, decreased morning stiffness and improved patient and practitioner assessments. Researchers monitored use of painkillers (acetaminophen up to three grams daily was the only medication allowed until week six) and the progression of the disease using blood and urine tests.

Of the 85 patients (42 in the placebo group, 41 in the adalimumab group), 35 in the placebo group and 38 in the adalimumab group received the two injections. Seventy-eight patients with at least one injection were analyzed (37 placebo and 41 adalimumab). The mean age of the patients was 62.5 years; 85 percent were women. Mean pain level at study beginning was 65.4 millimeters on a zero to 100 mm scale; and patients had a mean of 11 painful joints, and 5.9 clinically inflamed digital joints.

After six weeks of receiving adalimumab and placebo, researchers measured only a 2.5 millimeter difference in the average change in pain score between the groups. At week six, there was no difference between groups on the main outcome -- where they measured 50 percent improvement (35.1 percent in the adalimumab group versus 27.3 percent in the placebo group). The only difference recorded was a decrease in the number of swollen joints between week zero and week 26 in the adalimumab group. No other significant changes or concerns were reported.

"Our research found that two injections of anti-TNF failed to improve severe painful hand OA," says Xavier Chevalier, MD, PhD, head of the department of rheumatology at Hopital Henri Mondor in France and lead investigator of the study. "New trials are needed to find the right target in painful hand OA because this is a disease where we have no real therapy and the patients develop the feeling of a neglected disease."

Patients should talk to their rheumatologists to determine their best course of treatment.

This study was promoted by the APHP clinical research and osteoarthritis group of the French Society, and funding from Inserm pro A and a grant from ABBOTT laboratory.


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR). Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR). "Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests." ScienceDaily. ScienceDaily, 11 November 2012. <www.sciencedaily.com/releases/2012/11/121111153424.htm>.
American College of Rheumatology (ACR). (2012, November 11). Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2012/11/121111153424.htm
American College of Rheumatology (ACR). "Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/11/121111153424.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) — Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) — A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) — More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins